Pricing Log in Create free account
Friday 6 November 2026 Export BCRX’s income statement to Excel — free account

BioCryst Pharmaceuticals, Inc.

BCRX Healthcare Drug Manufacturers Specialty & Generic

BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.

Revenue
+13.1%
EPS
+150.0%
Free cash flow
−18.7%
Total debt
+15.2%

Quarter to September 2026, against a year earlier

7.55 0.69 −8.37%
Market cap
$2.0B
P/E
0.0×
Fwd P/E
−3.7×
Dividend yield
—
F-score
7/9
Altman Z
1.83
Beneish M
−2.27
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.90
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 2 — — 2 — 2 — — — — — —
Insider Ownership 14.07%

Capital & Financial Ratios $m

Size
Market Cap 1,950.00
Revenue ttm 961.51
Net income ttm (359.66)
Free cash flow ttm 366.40
Net debt Q 486.35
Valuation
P/E 0.00
Forward P/E (3.67) (negative: loss-making)
Price / sales 2.01
Forward P/S Powerpack
Price / FCF 5.27
Price / book 0.00
Financial health
Current ratio Q 2.71 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 2.52
Growth
Revenue growth Q +13.11% (above 0%: growing)
Operating income growth Q +80.22% (above 0%: growing)
EPS, this year −289.23% (below 0%: weak)
EPS, next year A +124.58% (at or above 15%: strong)
Revenue, next year A −18.83% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −21.46% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.5×, against a ten-year median of 10.2×; over the ten years it ranged from 1.8× in 2026 to 99.9× in 2021.
P/S against its own 10 years 1.50%
10-year low 10-year high
EV/Sales against its own 10 years 2.75%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 391 321 275 —
Receivables 57 79 107 122
Inventory 29 8 5 14
Other — — — —
496 422 404 531
2023 2024 2025 Q'26
Payables 21 12 16 15
ST’ Debt 24 33 52 —
Other — — — —
150 160 196 196

Compound Annual Growth %

10y 5y 3y
Sales 33.61% 117.89% 47.82%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.10 Actual 0.14

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.07 1.12 Beat by 1.05
Q1 FY26 0.06 −0.03 Miss by 0.09
Q2 FY26 0.14 0.30 Beat by 0.16
Q3 FY26 0.10 0.14 Beat by 0.04
Q4 FY26 0.12 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (2.98) 0.30 0.14 — —
’25 0.00 0.02 0.06 1.12 1.21
’24 (0.17) (0.06) (0.07) (0.13) (0.43)
’23 (0.28) (0.40) (0.19) (0.31) (1.18)
’22 (0.40) (0.32) (0.23) (0.38) (1.33)
’21 (0.36) (0.24) (0.33) (0.10) (1.03)
’20 (0.24) (0.24) (0.26) (0.34) (1.09)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 156 218 180 — —
’25 146 163 159 407 875
’24 93 109 117 132 451
’23 69 82 87 93 331
’22 50 66 76 80 271
’21 19 50 41 47 157
’20 5 3 6 4 18
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (62) 104 33 — —
’25 (28) 41 42 292 347
’24 (54) (1) 8 (5) (52)
’23 (48) (19) (20) (9) (95)
’22 (78) (28) (32) (24) (162)
’21 (61) (25) (23) (32) (142)
’20 (23) (31) (38) (43) (135)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (62) 104 33 — —
’25 (28) 41 40 292 345
’24 (54) (2) 8 (6) (53)
’23 (48) (19) (21) (9) (97)
’22 (78) (28) (33) (24) (163)
’21 (61) (26) (24) (34) (145)
’20 (23) (31) (38) (43) (136)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 26 25 21 49 18 157 271 331 451 875 962 +47.6% 710 736 830 (1.7%)
Gross margin, % 91.28 95.47 100.00 92.37 91.30 95.40 97.63 98.65 97.28 97.82 97.89 +6.5 pt
EBT (55) (66) (101) (109) (183) (182) (244) (226) (87) 267 (355) n/m
EBT margin, % (209.25) (261.18) (490.25) (222.99) (1,026.35) (115.68) (90.24) (68.26) (19.29) 30.56 (36.89) +239.8 pt
Net income (55) (66) (101) (109) (183) (184) (247) (227) (89) 264 (360) n/m
Per share, $
Per share, $ Revenue 0.36 0.30 0.20 0.42 0.11 0.88 1.46 1.72 2.18 4.17 3.76 +31.4%
Earnings (0.75) (0.78) (0.98) (0.94) (1.09) (1.03) (1.33) (1.18) (0.43) 1.26 (1.35) n/m
Cash flow (0.73) (0.49) (0.90) (0.77) (0.81) (0.79) (0.87) (0.49) (0.25) 1.66 1.44 n/m
Capex (0.07) 0.00 0.00 0.00 0.00 (0.01) (0.01) (0.01) (0.01) (0.01) 0.00 (20.5%)
Free cash flow (0.80) (0.49) (0.90) (0.78) (0.81) (0.81) (0.88) (0.51) (0.26) 1.65 1.43 n/m
Book value 0.02 0.99 0.48 0.33 (0.12) (0.60) (1.58) (2.37) (2.30) (0.57) (1.55) n/m
Shares, m 74 84 103 116 167 179 186 192 207 210 241 +12.3%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.24 0.00 0.6
P/S 17.79 18.24 40.32 8.17 69.96 15.78 7.86 3.52 3.45 1.87 2.01 18.7
P/B 297.04 5.48 16.91 10.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.0
EV/Sales 16.62 14.60 36.77 6.45 68.66 16.31 9.01 4.87 4.58 2.11 2.51 18.0
EV/FCF (7.46) (8.87) (8.17) (3.50) (9.02) (17.73) (14.95) (16.58) (38.84) 5.34 6.60 (12.0)
Cash, $m
Cash, $m Operating cash flow (53) (41) (93) (90) (135) (142) (162) (95) (52) 347 367 n/m
Capex (5) 0 0 0 (1) (2) (1) (2) (1) (2) (1) (10.6%)
Free cash flow (59) (41) (93) (90) (136) (145) (163) (97) (53) 345 366 n/m
Balance, $m
Balance, $m Working capital 13 51 45 72 218 462 411 346 262 208 335 +36.5%
Net debt (2) (92) (73) (84) (23) 82 312 447 510 206 486 n/m
Shareholders’ equity 2 84 49 38 (19) (107) (295) (456) (476) (119) (397) n/m
Returns, %
Returns, % ROA (51.97) (49.07) (62.29) (67.61) (71.69) (39.89) (43.42) (42.46) (17.65) 52.53 (69.33) +104.5 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 (544.24) 0.00 (4.71) 245.61 0.00 +245.6 pt
ROE (223.70) (154.16) (152.26) (248.94) (1,925.37) 291.59 123.07 60.40 19.08 (88.68) 91.60 +135.0 pt
People
People Employees 65 85 100 140 246 358 531 536 580 435 — +23.5%
Revenue/emp, $m 0.41 0.30 0.21 0.35 0.07 0.44 0.51 0.62 0.78 2.01 — +19.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

BioCryst Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RGC Regencell Bioscience Holdings Limited $2.6B — (loss-making) — — — +57.15% (above 0%: growing) 0.00% — Compare
HCM HUTCHMED (China) Limited Sponsored ADR $2.5B — (loss-making) — +510.07% (above 0%: growing) +419.25% (above 0%: growing) +113.21% (above 0%: growing) 60.90% 0.00% Compare
XERS Xeris Biopharma Holdings, Inc. $2.4B — (loss-making) — (loss-making) +44.16% (above 0%: growing) +1,478.95% (above 0%: growing) +93.18% (above 0%: growing) 88.41% 15.78% Compare
PRGO Perrigo Company plc $2.2B — (loss-making) — (loss-making) −5.24% (below 0%: shrinking) n/m +138.48% (above 0%: growing) 32.45% 2.34% Compare
TRLV Trulieve Cannabis Corp. $2.1B — (loss-making) — (loss-making) −20.12% (below 0%: shrinking) n/m +24.49% (above 0%: growing) 64.30% 0.00% Compare
PBH Prestige Consumer Healthcare Inc. $2.1B 13.7× 11.7× +22.69% (above 0%: growing) −38.37% (below 0%: shrinking) −38.18% (below 0%: shrinking) 51.30% 24.00% Compare
BCRX BioCryst Pharmaceuticals, Inc. $2.0B — (loss-making) — (loss-making) +13.11% (above 0%: growing) +150.00% (above 0%: growing) −18.69% (below 0%: shrinking) 99.13% 29.58%
ALVO Alvotech $1.8B — (loss-making) 111× +2,310.95% (above 0%: growing) −99.51% (below 0%: shrinking) −496.58% (below 0%: shrinking) 56.47% 9.14% Compare
ANIP ANI Pharmaceuticals, Inc. $1.6B 13.3× 14.3× +27.64% (above 0%: growing) +29.41% (above 0%: growing) +85.49% (above 0%: growing) 61.64% 18.01% Compare
Median of peers $2.1B — 14.3× +27.64% +29.41% +71.32% 58.69% 9.14%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 23 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 12.95m 1.16m 104.70
2024 8.32m 10.98m 100.94
2023 4.78m (3.69m) 80.40
2022 6.98m 4.01m 154.09
2021 7.06m 17.05m 185.91

Ownership

Directors and executive officers, together 3.80%
The Vanguard Group 8.20%
BlackRock, Inc. 6.90%
RA Capital Healthcare Fund, L.P.200 Berkeley Street, 6.00%
Deerfield Partners, L.P. 5.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

BioCryst Pharmaceuticals, Inc. (BCRX) Latest News

5 Nov

Impact 3 · · GuruFocus.com

4 Nov

Impact 3 · · Moby
Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

29 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks
Impact 3 · · Zacks

28 Oct

Impact 3 · · Zacks

21 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

15 Oct

Impact 4 · · Insider Monkey

5 Oct

Impact 4 · · GlobeNewswire

29 Sep

Impact 3 · · Insider Monkey

23 Sep

Impact 4 · · Insider Monkey

21 Sep

Impact 3 · · Schaeffer's Investment Research

18 Sep

Impact 4 · · MarketBeat

17 Sep

Impact 4 ·

14 Sep

Impact 3 ·

10 Sep

Impact 3 · · Stocktwits
Impact 3 ·

8 Sep

Impact 4 · · Stocktwits
Impact 3 ·

28 Aug

Impact 4 · · Stocktwits

25 Aug

Impact 4 ·

13 Aug

Impact 3 ·

12 Aug

Impact 3 · · The Motley Fool transcript

11 Aug

Impact 4 · · 24/7 Wall St.

5 Aug

Impact 4 · transcript

BCRX metrics, ten years each

stockrow.com/BCRX · Data as of Nov 4, 2026 · For information only; not investment advice. · © 2026 stockrow.com